(Q36232646)

12 August 2017

1 reference

title

Cetuximab therapy and symptomatic hypomagnesemia (English)

1 reference

12 August 2017

1 reference

Deborah Schrag

1

1 reference

12 August 2017

Ki Young Chung

series ordinal

2

1 reference

12 August 2017

Carlos Flombaum

series ordinal

3

1 reference

12 August 2017

Leonard Saltz

series ordinal

4

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 August 2005

1 reference

Journal of the National Cancer Institute

12 August 2017

published in

1 reference

12 August 2017

volume

97

1 reference

12 August 2017

issue

16

1 reference

12 August 2017

page(s)

1221-1224

1 reference

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI242

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI242

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI242

Cisplatin and hypomagnesemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI242

Magnesium homeostasis and clinical disorders of magnesium deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI242

Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI242

Disruption of TRPM6/TRPM7 complex formation by a mutation in the TRPM6 gene causes hypomagnesemia with secondary hypocalcemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI242

Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI242

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI242

21 January 2018

Identifiers

DOI

10.1093/JNCI/DJI242

1 reference

12 August 2017

1 reference